Virtual discovery of melatonin receptor ligands to modulate circadian rhythms.
Animals
Circadian Rhythm
/ drug effects
Darkness
Drug Evaluation, Preclinical
Drug Inverse Agonism
Female
Humans
Ligands
Light
Male
Mice
Mice, Knockout
Molecular Docking Simulation
Receptor, Melatonin, MT1
/ agonists
Receptor, Melatonin, MT2
/ agonists
Receptors, Melatonin
/ agonists
Small Molecule Libraries
/ pharmacology
Substrate Specificity
/ genetics
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
03
08
2019
accepted:
31
01
2020
pubmed:
11
2
2020
medline:
2
6
2020
entrez:
11
2
2020
Statut:
ppublish
Résumé
The neuromodulator melatonin synchronizes circadian rhythms and related physiological functions through the actions of two G-protein-coupled receptors: MT
Identifiants
pubmed: 32040955
doi: 10.1038/s41586-020-2027-0
pii: 10.1038/s41586-020-2027-0
pmc: PMC7134359
mid: NIHMS1555350
doi:
Substances chimiques
Ligands
0
Receptor, Melatonin, MT1
0
Receptor, Melatonin, MT2
0
Receptors, Melatonin
0
Small Molecule Libraries
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
609-614Subventions
Organisme : NIEHS NIH HHS
ID : R21 ES023684
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM071896
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001412
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM127086
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM133836
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM122481
Pays : United States
Organisme : NIDDK NIH HHS
ID : U24 DK116195
Pays : United States
Organisme : NIDA NIH HHS
ID : R37 DA045657
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001413
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Zisapel, N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br. J. Pharmacol. 175, 3190–3199 (2018).
pubmed: 29318587
pmcid: 6057895
Dubocovich, M. L. et al. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol. Rev. 62, 343–380 (2010).
pubmed: 20605968
pmcid: 2964901
Liu, J. et al. MT1 and MT2 melatonin receptors: a therapeutic perspective. Annu. Rev. Pharmacol. Toxicol. 56, 361–383 (2016).
pubmed: 26514204
Dubocovich, M. L. Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med. 8, 34–42 (2007).
pubmed: 18032103
Mundey, K., Benloucif, S., Harsanyi, K., Dubocovich, M. L. & Zee, P. C. Phase-dependent treatment of delayed sleep phase syndrome with melatonin. Sleep 28, 1271–1278 (2005).
pubmed: 16295212
Rajaratnam, S. M. et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 373, 482–491 (2009).
pubmed: 19054552
Lewy, A. J. et al. The phase shift hypothesis for the circadian component of winter depression. Dialogues Clin. Neurosci. 9, 291–300 (2007).
pubmed: 17969866
pmcid: 3202495
Jockers, R. et al. Update on melatonin receptors: IUPHAR Review 20. Br. J. Pharmacol. 173, 2702–2725 (2016).
pubmed: 27314810
pmcid: 4995287
de Bodinat, C. et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat. Rev. Drug Discov. 9, 628–642 (2010).
pubmed: 20577266
Descamps-François, C. et al. Design and synthesis of naphthalenic dimers as selective MT
pubmed: 12646022
Spadoni, G. et al. Bivalent ligand approach on N-2-[(3-methoxyphenyl)methylamino]ethylacetamide: synthesis, binding affinity and intrinsic activity for MT
pubmed: 21775151
Zlotos, D. P., Riad, N. M., Osman, M. B., Dodda, B. R. & Witt-Enderby, P. A. Novel difluoroacetamide analogues of agomelatine and melatonin: probing the melatonin receptors for MT
Stauch, B. et al. Structural basis of ligand recognition at the human MT
pubmed: 31019306
pmcid: 6696938
Johansson, L. C. et al. XFEL structures of the human MT
pubmed: 31019305
pmcid: 6589158
Lyu, J. et al. Ultra-large library docking for discovering new chemotypes. Nature 566, 224–229 (2019).
pubmed: 30728502
pmcid: 6383769
Weiss, D. R. et al. Selectivity challenges in docking screens for GPCR targets and antitargets. J. Med. Chem. 61, 6830–6845 (2018).
pubmed: 29990431
pmcid: 6105036
Manglik, A. et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature 537, 185–190 (2016).
pubmed: 27533032
pmcid: 5161585
Huang, X. P. et al. Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65. Nature 527, 477–483 (2015).
pubmed: 26550826
pmcid: 4796946
Lansu, K. et al. In silico design of novel probes for the atypical opioid receptor MRGPRX2. Nat. Chem. Biol. 13, 529–536 (2017).
pubmed: 28288109
pmcid: 5391270
Sterling, T. & Irwin, J. J. ZINC 15—ligand discovery for everyone. J. Chem. Inf. Model. 55, 2324–2337 (2015).
pubmed: 26479676
pmcid: 4658288
Coleman, R. G., Carchia, M., Sterling, T., Irwin, J. J. & Shoichet, B. K. Ligand pose and orientational sampling in molecular docking. PLoS ONE 8, e75992 (2013).
pubmed: 24098414
pmcid: 3787967
Bento, A. P. et al. The ChEMBL bioactivity database: an update. Nucleic Acids Res. 42, D1083–D1090 (2014).
pubmed: 24214965
Irwin, J. J. & Shoichet, B. K. Docking screens for novel ligands conferring new biology. J. Med. Chem. 59, 4103–4120 (2016).
pubmed: 26913380
pmcid: 4865415
Muchmore, S. W. et al. Application of belief theory to similarity data fusion for use in analog searching and lead hopping. J. Chem. Inf. Model. 48, 941–948 (2008).
pubmed: 18416545
Katritch, V. et al. Structure-based discovery of novel chemotypes for adenosine A
pubmed: 20095623
pmcid: 2826142
de Graaf, C. et al. Crystal structure-based virtual screening for fragment-like ligands of the human histamine H
pubmed: 22007643
pmcid: 3228891
Männel, B. et al. Structure-guided screening for functionally selective D
pubmed: 28846380
Kiss, R. et al. Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. J. Med. Chem. 51, 3145–3153 (2008).
pubmed: 18459760
Congreve, M. et al. Discovery of 1,2,4-triazine derivatives as adenosine A
pubmed: 22220592
pmcid: 3308197
Langmead, C. J. et al. Identification of novel adenosine A
pubmed: 22250781
pmcid: 3308209
Adamah-Biassi, E. B., Stepien, I., Hudson, R. L. & Dubocovich, M. L. Effects of the melatonin receptor antagonist (MT2)/inverse agonist (MT1) luzindole on re-entrainment of wheel running activity and spontaneous homecage behaviors in C3H/HeN Mice. FASEB J. 26, 1042.5 (2012).
Dubocovich, M. L. Luzindole (N-0774): a novel melatonin receptor antagonist. J. Pharmacol. Exp. Ther. 246, 902–910 (1988).
pubmed: 2843633
Browning, C., Beresford, I., Fraser, N. & Giles, H. Pharmacological characterization of human recombinant melatonin mt
pubmed: 10696085
pmcid: 1571913
Dubocovich, M. L., Yun, K., Al-Ghoul, W. M., Benloucif, S. & Masana, M. I. Selective MT
pubmed: 9737724
Benloucif, S. & Dubocovich, M. L. Melatonin and light induce phase shifts of circadian activity rhythms in the C3H/HeN mouse. J. Biol. Rhythms 11, 113–125 (1996).
pubmed: 8744239
Burgess, H. J., Revell, V. L., Molina, T. A. & Eastman, C. I. Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. J. Clin. Endocrinol. Metab. 95, 3325–3331 (2010).
pubmed: 20410229
pmcid: 2928909
Rawashdeh, O., Hudson, R. L., Stepien, I. & Dubocovich, M. L. Circadian periods of sensitivity for ramelteon on the onset of running-wheel activity and the peak of suprachiasmatic nucleus neuronal firing rhythms in C3H/HeN mice. Chronobiol. Int. 28, 31–38 (2011).
pubmed: 21182402
pmcid: 5040068
Van Reeth, O. et al. Comparative effects of a melatonin agonist on the circadian system in mice and Syrian hamsters. Brain Res. 762, 185–194 (1997).
pubmed: 9262172
Erşahin, C., Masana, M. I. & Dubocovich, M. L. Constitutively active melatonin MT
pubmed: 11937107
Soares, J. M. Jr, Masana, M. I., Erşahin, C. & Dubocovich, M. L. Functional melatonin receptors in rat ovaries at various stages of the estrous cycle. J. Pharmacol. Exp. Ther. 306, 694–702 (2003).
pubmed: 12721330
Lewy, A. J. et al. The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light. Chronobiol. Int. 15, 71–83 (1998).
pubmed: 9493716
Gillette, M. U. & Mitchell, J. W. Signaling in the suprachiasmatic nucleus: selectively responsive and integrative. Cell Tissue Res. 309, 99–107 (2002)
pubmed: 12111540
Reid, K. J. et al. Familial advanced sleep phase syndrome. Arch. Neurol. 58, 1089–1094 (2001).
pubmed: 11448298
Kufareva, I., Gustavsson, M., Zheng, Y., Stephens, B. S. & Handel, T. M. What do structures tell us about chemokine receptor function and antagonism? Annu. Rev. Biophys. 46, 175–198 (2017).
pubmed: 28532213
pmcid: 5764094
Cooke, R. M., Brown, A. J., Marshall, F. H. & Mason, J. S. Structures of G protein-coupled receptors reveal new opportunities for drug discovery. Drug Discov. Today 20, 1355–1364 (2015).
pubmed: 26303408
Lefkowitz, R. J., Mullikin, D. & Caron, M. G. Regulation of β-adrenergic receptors by guanyl-5′-yl imidodiphosphate and other purine nucleotides. J. Biol. Chem. 251, 4686–4692 (1976).
pubmed: 947904
Word, J. M., Lovell, S. C., Richardson, J. S. & Richardson, D. C. Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J. Mol. Biol. 285, 1735–1747 (1999).
pubmed: 9917408
Weiner, S. J. et al. A new force field for molecular mechanical simulation of nucleic acids and proteins. J. Am. Chem. Soc. 106, 765–784 (1984).
Carlsson, J. et al. Structure-based discovery of A
pubmed: 20405927
pmcid: 2865168
Gallagher, K. & Sharp, K. Electrostatic contributions to heat capacity changes of DNA-ligand binding. Biophys. J. 75, 769–776 (1998).
pubmed: 9675178
pmcid: 1299751
Mysinger, M. M. & Shoichet, B. K. Rapid context-dependent ligand desolvation in molecular docking. J. Chem. Inf. Model. 50, 1561–1573 (2010).
pubmed: 20735049
Southan, C. et al. The IUPHAR/BPS guide to pharmacology in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res. 44, D1054–D1068 (2016).
pubmed: 26464438
Tolmachev, A. et al. Expanding synthesizable space of disubstituted 1,2,4-oxadiazoles. ACS Comb. Sci. 18, 616–624 (2016).
pubmed: 27548754
Kroeze, W. K. et al. PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nat. Struct. Mol. Biol. 22, 362–369 (2015).
pubmed: 25895059
pmcid: 4424118
Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A. & Novick, S. A simple method for quantifying functional selectivity and agonist bias. ACS Chem. Neurosci. 3, 193–203 (2012).
pubmed: 22860188
Kenakin, T. Biased receptor signaling in drug discovery. Pharmacol. Rev. 71, 267–315 (2019).
pubmed: 30914442
Longo, P. A., Kavran, J. M., Kim, M. S. & Leahy, D. J. Transient mammalian cell transfection with polyethylenimine (PEI). Methods Enzymol. 529, 227–240 (2013).
pubmed: 24011049
pmcid: 4012321
Besnard, J. et al. Automated design of ligands to polypharmacological profiles. Nature 492, 215–220 (2012).
pubmed: 23235874
Popovska-Gorevski, M., Dubocovich, M. L. & Rajnarayanan, R. V. Carbamate insecticides target human melatonin receptors. Chem. Res. Toxicol. 30, 574–582 (2017).
pubmed: 28027439
pmcid: 5318275
Cheng, Y.-C. & Prusoff, W. H. Relationship between the inhibition constant (K
pubmed: 4202581
Sumaya, I. C., Masana, M. I. & Dubocovich, M. L. The antidepressant-like effect of the melatonin receptor ligand luzindole in mice during forced swimming requires expression of MT
pubmed: 16098095
Dubocovich, M. L., Hudson, R. L., Sumaya, I. C., Masana, M. I. & Manna, E. Effect of MT
pubmed: 16098087